Search
- Sep 18
Generate Biomedicines' Mike Nally on Thursday's $273M Series C and computational drug development
Mike Nally describes Generate's near term programs how he sees computational advances changing where the field is headed over the long term.
- Jan 11
AI in biotech with Generate Biomedicines’ Mike Nally
Generate Biomedicine's Mike Nally describes how AI might impact biotech in the future at #JPM23.
